Drug intelligence / Profile preview

dynorphin

Development stage
Unknown
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Intravenous, Intrathecal, Intracerebroventricular, Intracerebral
01

Overview

Dynorphin is a family of endogenous opioid peptides produced in the body from the precursor protein prodynorphin. These neuropeptides are primarily known for their potent activity as agonists at the kappa opioid receptor (KOR), where they modulate pain perception, stress responses, emotional processing, and addiction-related behaviors. Dynorphins are distributed throughout the brain and spinal cord and play complex roles in both analgesia and dysphoria. In addition to activating KORs, certain forms of dynorphin can interact with non-opioid targets such as bradykinin receptors and NMDA receptors—modulating neuronal excitability through multiple pathways. Dynorphins have been investigated for their potential therapeutic role in conditions like drug addiction (notably cocaine and heroin dependence), neuropathic pain, epilepsy (as natural anticonvulsants), anxiety disorders, depression, and other psychiatric or neurological diseases. There is ongoing research into gene therapy approaches using prodynorphin to suppress seizures in epilepsy models.

Other names
dynorphinsdynorphin Adynorphin Bbig dynorphin
02

Targets

Beyond the preview

Go deeper on dynorphin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dynorphin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call